Esophageal adenocarcinoma

Reflux-promoting drugs may raise risk for esophageal adenocarcinoma.

August 3, 2000

NEW YORK, August 2 (Praxis Press) An increase in the incidence of esophageal adenocarcinoma was first reported in the 1970s, a time period during which drugs that relax the lower esophageal sphincter (LES) had gained widespread use. Lagergren and colleagues studied the association of upper gastrointestinal tract cancers and use of several classes of LES-relaxing drugs. The study included 189 subjects with esophageal adenocarcinoma, 262 with adenocarcinoma of the gastric cardia, 167 with esophageal squamous cell carcinoma, and 820 control subjects. When compared with patients who had never used LES-relaxing drugs, patients who used them daily for more than five years had an estimated incidence rate ratio of 3.8 for esophageal adenocarcinoma; this association was strongest for anticholinergic drugs. In contrast, no association was noted for adenocarcinoma of the gastric cardia or esophageal squamous cell carcinoma. The therapeutic benefits of LES-relaxing drugs may be slightly offset by an increased risk of esophageal adenocarcinoma.

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Gut Feeling
    Daily News Gut Feeling

    Sensory cells of the mouse intestine let the brain know if certain compounds are present by speaking directly to gut neurons via serotonin.

  3. Athletes’ Microbiomes Differ from Nonathletes
  4. Government Nixes Teaching Evolution in Turkish Schools
AAAS